Summary
We propose a new method to estimate the ratio between the basic reproduction numbers of a newly emerged variant and the one currently dominating. We use public data of two kinds: the proportions of the daily infected from each strain obtained from a random sample that has been sequenced, and the epidemic curves of total infections and recoveries. Our method is based on a new discrete-time SIR model with two strains, considered both in the deterministic and stochastic versions. In the deterministic case we use maximum likelihood, while in the stochastic setting, since we need to reconstruct the missing incidence and prevalence information of the new variant, we decided to use a hierarchical Bayesian hidden Markov model. This new methodology is applied to data from the Piedmont Italian region in December-January 2022, when the Omicron variant started to be observed and quickly became prevalent. With both approaches, we obtain an estimate of the contagiousness ratio that is consistent with other studies specifically designed for the aim.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Regione Piemonte, INFRA-P2 COVID, Reg. (UE) 1407/2013, CID 378-26, Progetto SORGENTE, CUP E15F21003680007
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Istituto Superiore di Sanita', Monitoraggio delle varianti del virus SARS-CoV-2 di interesse in sanita' pubblica in Italia, https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-indagini-rapide Presidenza del Consiglio dei Ministri - Dipartimento della Protezione Civile, https://github.com/pcm-dpc/COVID-19
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
giulia.dellacroce{at}polito.it, enrico.bibbona{at}polito.it
Data Availability
All data produced are available online at: Istituto Superiore di Sanita', Monitoraggio delle varianti del virus SARS-CoV-2 di interesse in sanita' pubblica in Italia, https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-indagini-rapide Presidenza del Consiglio dei Ministri - Dipartimento della Protezione Civile, https://github.com/pcm-dpc/COVID-19
https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-indagini-rapide